
Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence.

Beni Lestari<sup>1</sup>, Ikuko Nakamae<sup>1</sup>, Noriko Yoneda-Kato<sup>1</sup>, Tsumoru Morimoto<sup>2</sup>, Shigehiko Kanaya<sup>3</sup>, Takashi Yokoyama<sup>1</sup>, Masafumi Shionyu<sup>4</sup>, Tsuyoshi Shirai<sup>4</sup>, Edy Meiyanto<sup>5</sup>, and Jun-ya Kato<sup>1\*</sup>

<sup>1</sup>Laboratory of Tumor Cell Biology, Division of Biological Science, <sup>2</sup>Laboratory of Synthetic Organic Chemistry, Division of Materials Science, <sup>3</sup>Laboratory of Computational Systems Biology, Division of Information Science, Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara, Japan, <sup>4</sup>Nagahama Institute of Bio-Science and Technology, Nagahama, Japan, <sup>5</sup>Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.

Figure S1 - Related to Figure 2



## Legend for Supplementry Fig. S1

K562 cells (5 x  $10^5$  cells/mL) were treated with PGV-1 (0.8  $\mu$ M) for 0.5, 2, 4, 8, 12, 24, 48, and 72 hr, and then subjected to cell cycle analysis. The percentages of cells in each phase are shown as the mean  $\pm$  SD from three independent experiments.

Figure S2 – Related to Figure 3

